PROTACs: The Future of Leukemia Therapeutics.

Anwar, Zubair; Ali, Muhammad Shahzad; Galvano, Antonio; Perez, Alessandro; La Mantia, Maria; Bukhari, Ihtisham; Swiatczak, Bartlomiej.

Afiliación

Anwar Z; Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy.
Ali MS; Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Turin, Italy.
Galvano A; Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy.
Perez A; Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy.
La Mantia M; Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, Uiniversity of Palermo, Palermo, Italy.
Bukhari I; The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Swiatczak B; Department of History of Science and Scientific Archeology, University of Science and Technology of China, Hefei, China.

Front Cell Dev Biol ; 10: 851087, 2022.

Article en En | MEDLINE | ID: mdl-36120561

ABSTRACT

The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteasome pathway. This review mainly focuses on the general design and functioning of PROTACs as well as current advancements in the development of PROTACs as anticancer therapies. Particular emphasis is given to PROTACs designed against various types of Leukemia/Blood malignancies.

Palabras clave

PROTACs; anticancer therapeutics; cancer; leukemia; linker